/Solventum%20Corp%20logo%20on%20phone-by%20Below%20the%20Sky%20via%20Shutterstock.jpg)
Solventum Corporation (SOLV), based in Maplewood, Minnesota, is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs. With a market cap of $12.6 billion, the company’s broad portfolio of solutions leverages material and data science, clinical research, and digital capabilities. Solventum operates in the areas of separation and purification, health information, medical solutions, medical device components, and the oral care market. The leading global healthcare company is expected to announce its fiscal second-quarter earnings for 2025 after the market closes on Thursday, Aug. 7.
Ahead of the event, analysts expect SOLV to report a profit of $1.45 per share on a diluted basis, down 7.1% from $1.56 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.
For the full year, analysts expect SOLV to report EPS of $5.58, down 16.7% from $6.70 in fiscal 2024. However, its EPS is expected to rise 3.1% year-over-year to $5.75 in fiscal 2026.
SOLV stock has outperformed the S&P 500 Index’s ($SPX) 14.5% gains over the past 52 weeks, with shares up 31.4% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund’s (XLV) 8.3% dip over the same time frame.
On May 8, SOLV reported its Q1 results, and its shares closed up by 11.9% in the following two trading sessions. Its adjusted EPS of $1.34 beat Wall Street's expectations of $1.19. The company’s revenue was $2.1 billion, exceeding Wall Street forecasts of $2 billion. SOLV expects full-year adjusted EPS in the range of $5.45 to $5.65.
Analysts’ consensus opinion on SOLV stock is reasonably bullish, with an overall “Moderate Buy” rating. Out of 12 analysts covering the stock, four advise a “Strong Buy” rating, seven give a “Hold,” and one recommends a “Strong Sell.” SOLV’s average analyst price target is $85.50, indicating a potential upside of 14.9% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
